Because of these multiple pathological pathways, treatment of patients with either TTP or TMA associated to HIV should be directed to rapidly control the viral load, reduce the virus-induced immunosuppression, and replace the defective ADAMTS13 and coagulation proteins by TPE. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.